ATE507209T1 - Referenzstandard zur charakterisierung von rosuvastatin - Google Patents

Referenzstandard zur charakterisierung von rosuvastatin

Info

Publication number: ATE507209T1
Authority: AT; Austria
Prior art keywords: rosuvastatin; characterization; reference standard; standard; analysis
Prior art date: 2003-12-02

Application number

AT04812772T

Other languages

English (en)

Inventor

Nina Finkelstein

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-02

Filing date

2004-12-02

Publication date

2011-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-02 Application filed by Teva Pharma filed Critical Teva Pharma

2011-05-15 Application granted granted Critical

2011-05-15 Publication of ATE507209T1 publication Critical patent/ATE507209T1/de

Links

BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
229960000672 rosuvastatin Drugs 0.000 title abstract 3
238000012512 characterization method Methods 0.000 title 1
239000007857 degradation product Substances 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT04812772T 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin ATE507209T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52644903P	2003-12-02	2003-12-02
PCT/US2004/040329 WO2005056534A1 (en)	2003-12-02	2004-12-02	Reference standard for characterization of rosuvastatin

Publications (1)

Publication Number	Publication Date
ATE507209T1 true ATE507209T1 (de)	2011-05-15

Family

ID=34676616

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04812772T ATE507209T1 (de)	2003-12-02	2004-12-02	Referenzstandard zur charakterisierung von rosuvastatin

Country Status (13)

Country	Link
US (6)	US7244844B2 (de)
EP (1)	EP1689723B1 (de)
JP (1)	JP4733047B2 (de)
KR (1)	KR100887264B1 (de)
CN (1)	CN1894221B (de)
AT (1)	ATE507209T1 (de)
CA (1)	CA2546894C (de)
DE (1)	DE602004032465D1 (de)
ES (1)	ES2364143T3 (de)
IL (1)	IL175511A (de)
PT (1)	PT1689723E (de)
TW (1)	TWI351958B (de)
WO (1)	WO2005056534A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
CN1894221B (zh) *	2003-12-02	2012-08-08	特瓦制药工业有限公司	用于表征罗苏伐他汀的参照标准品
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
TWI345562B (en)	2005-02-22	2011-07-21	Teva Pharma	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2007071357A2 (en) *	2005-12-20	2007-06-28	Lek Pharmaceuticals D.D.	Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
BRPI0803085A2 (pt) *	2007-03-13	2011-08-30	Teva Pharma	forma triol de rosuvastatina
EP2189456A1 (de) *	2008-11-14	2010-05-26	LEK Pharmaceuticals d.d.	Neue Omeprazol-Verbindungen
CN102325755B (zh)	2008-12-30	2015-07-01	艾科尔公司	取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
CN103454352B (zh) *	2013-07-30	2015-07-15	广东先强药业有限公司	一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) *	2014-02-11	2014-05-07	润泽制药(苏州)有限公司	瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) *	2018-03-02	2018-08-14	海南通用三洋药业有限公司	一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) *	2018-07-23	2020-06-02	唯智医药科技（北京）有限公司	一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181B (zh) *	2021-12-23	2024-06-18	浙江海翔川南药业有限公司	一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US37314A (en) *		1863-01-06		Improved composition for lemonade
US633198A (en) *	1899-02-08	1899-09-19	Wilhelm Magnus Hoekerstedt	Automatic-lighting torch.
US4231938A (en) *	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
US4444784A (en) *	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
MX7065E (es) *	1980-06-06	1987-04-10	Sankyo Co	Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) *	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) *	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0554455B1 (de)	1991-06-19	1997-12-17	Shionogi Seiyaku Kabushiki Kaisha	Optisch aktives zwischenprodukt und dessen herstellung
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
GB9626746D0 (en)	1996-12-23	1997-02-12	Knoll Ag	Process
GB9812413D0 (en) *	1998-06-10	1998-08-05	Glaxo Group Ltd	Compound and its use
SI20070A (sl)	1998-09-18	2000-04-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
GB0001621D0 (en) *	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0028429D0 (en) *	2000-11-22	2001-01-10	Astrazeneca Ab	Therapy
CA2450820C (en) *	2001-08-16	2011-03-15	Teva Pharmaceutical Industries Ltd.	Processes for preparing calcium salt forms of statins
KR20040026705A (ko) *	2001-08-16	2004-03-31	테바 파마슈티컬 인더스트리즈 리미티드	스타틴의 칼슘 염 형태의 제조 방법
SE0103509D0 (sv)	2001-10-19	2001-10-19	Astrazeneca Ab	Rosuvastatin in pre demented states
KR100511533B1 (ko)	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EA200401533A1 (ru)	2002-05-21	2005-06-30	Ранбакси Лабораторис Лимитед	Способ получения росувастатина
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
US7566782B2 (en)	2002-12-10	2009-07-28	Ranbaxy Laboratories Limited	Process for the preparation of rosuvastatin
WO2005021511A1 (en)	2003-08-27	2005-03-10	Hetero Drugs Limited	A novel process for amorphous rosuvastatin calcium
EP1678148A1 (de)	2003-10-22	2006-07-12	Ranbaxy Laboratories Limited	Verfahren zur herstellung von amorphen rosuvastatin-calcium
WO2005051921A1 (en) *	2003-11-24	2005-06-09	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) *	2003-12-02	2012-08-08	特瓦制药工业有限公司	用于表征罗苏伐他汀的参照标准品
WO2006035277A2 (en)	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
JP2008528542A (ja)	2005-01-31	2008-07-31	チバホールディングインコーポレーテッド	ロスバスタチンカルシウム塩の結晶形
US20090124803A1 (en)	2005-03-22	2009-05-14	Pandurang Balwant Deshpande	Process for preparation of rosuvastatin
WO2006106526A1 (en)	2005-04-04	2006-10-12	Unichem Laboratories Limited	Process for preparation of calcium salt of rosuvastatin
EP2508514B1 (de)	2005-06-24	2017-10-18	LEK Pharmaceuticals d.d.	Verfahren zur Herstellung von amorphem Rosuvastatincalcium frei von Verunreinigungen
ES2564807T5 (es)	2005-06-24	2019-02-26	Lek Pharmaceuticals	Proceso para preparación de rosuvastatina de calcio amorfa pura
GB0514078D0 (en)	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process

2004
- 2004-12-02 CN CN2004800359220A patent/CN1894221B/zh not_active Expired - Fee Related
- 2004-12-02 CA CA002546894A patent/CA2546894C/en not_active Expired - Fee Related
- 2004-12-02 EP EP04812772A patent/EP1689723B1/de not_active Revoked
- 2004-12-02 KR KR1020067013302A patent/KR100887264B1/ko not_active Expired - Fee Related
- 2004-12-02 PT PT04812772T patent/PT1689723E/pt unknown
- 2004-12-02 TW TW093137210A patent/TWI351958B/zh not_active IP Right Cessation
- 2004-12-02 ES ES04812772T patent/ES2364143T3/es not_active Expired - Lifetime
- 2004-12-02 US US11/001,912 patent/US7244844B2/en not_active Expired - Lifetime
- 2004-12-02 DE DE602004032465T patent/DE602004032465D1/de not_active Expired - Lifetime
- 2004-12-02 AT AT04812772T patent/ATE507209T1/de not_active IP Right Cessation
- 2004-12-02 JP JP2006541502A patent/JP4733047B2/ja not_active Expired - Fee Related
- 2004-12-02 WO PCT/US2004/040329 patent/WO2005056534A1/en not_active Ceased
2006
- 2006-05-09 IL IL175511A patent/IL175511A/en active IP Right Grant
2007
- 2007-06-25 US US11/823,045 patent/US7692010B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/821,968 patent/US7692008B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,019 patent/US7692009B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,013 patent/US7741482B2/en not_active Expired - Fee Related
2009
- 2009-01-27 US US12/322,042 patent/US8487097B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4733047B2 (ja)	2011-07-27
JP2007512354A (ja)	2007-05-17
EP1689723A1 (de)	2006-08-16
US20070249831A1 (en)	2007-10-25
DE602004032465D1 (de)	2011-06-09
US7741482B2 (en)	2010-06-22
IL175511A (en)	2011-11-30
US20070255059A1 (en)	2007-11-01
US8487097B2 (en)	2013-07-16
US20090188305A1 (en)	2009-07-30
IL175511A0 (en)	2006-09-05
TWI351958B (en)	2011-11-11
TW200522959A (en)	2005-07-16
WO2005056534A1 (en)	2005-06-23
ES2364143T3 (es)	2011-08-25
KR20060098396A (ko)	2006-09-18
US7692009B2 (en)	2010-04-06
CN1894221B (zh)	2012-08-08
CA2546894C (en)	2009-09-08
PT1689723E (pt)	2011-07-06
KR100887264B1 (ko)	2009-03-06
EP1689723B1 (de)	2011-04-27
CN1894221A (zh)	2007-01-10
US7244844B2 (en)	2007-07-17
US20070244321A1 (en)	2007-10-18
CA2546894A1 (en)	2005-06-23
US20070249830A1 (en)	2007-10-25
US7692008B2 (en)	2010-04-06
US20050187234A1 (en)	2005-08-25
US7692010B2 (en)	2010-04-06

Legal Events

Date	Code	Title	Description
2011-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE269295T1 (de)	2004-07-15	Btk inhibitoren und verfahren zur identifizierung und verwendung
DE602004032465D1 (de)	2011-06-09	Referenzstandard zur charakterisierung von rosuvastatin
ATE307618T1 (de)	2005-11-15	Vorrichtung zur abgabe von flüchtigen stoffen
ATE335722T1 (de)	2006-09-15	Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DE60007095D1 (de)	2004-01-22	Calanolide zur hemmung von btk
ATE485366T1 (de)	2010-11-15	Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
FI20030609L (fi)	2004-10-23	Analyysi- ja kasvatuslaitteisto
DE60301922D1 (de)	2006-03-02	Vorrichtung zur Entnahme von Objekten
DE602004024642D1 (de)	2010-01-28	Vorrichtung zur verlängerten freisetzung und methode zur okularen verabreichung von carboanhydrase inhibitoren
DE602004025507D1 (de)	2010-03-25	Vanillin-polymere zwecks verwendung zur verdunklung der haut
EA200500064A1 (ru)	2006-06-30	Многофункциональные маркеры продуктов и способы их получения и применения
DE60223780D1 (de)	2008-01-10	Verfahren zur Entfernung von Kunstrasenböden, entsprechende Verwendung und Produkt
UY27192A1 (es)	2002-09-30	Inhibidores de peptido-deformilasa
MY133625A (en)	2007-11-30	Peptide deformylase inhibitors
DE60333196D1 (de)	2010-08-12	Atemerfrischer und mundpflegeprodukt unter verwendung von kardamom l
AU2003223634A1 (en)	2004-11-26	Peptide deformylase inhibitors
BR0316544A (pt)	2005-10-04	Compostos calcilìticos
IL173929A0 (en)	2006-07-05	Analogues of kahalalide f and pharmaceutical compositions containing the same
DE602004002532D1 (de)	2006-11-09	Vorrichtung zur Herstellung von Broschüren
ATE548037T1 (de)	2012-03-15	Peptid-deformylase-hemmer
DE60207833D1 (de)	2006-01-12	Peptiddeformylase-hemmer
IS7441A (is)	2004-09-08	Peptíðdeformýlasatálmar
DE502004010446D1 (de)	2010-01-14	Osteosyntheseplatte zur operativen versorgung von knochenfrakturen
DE60232650D1 (de)	2009-07-30	Peptiddeformylaseinhibitoren
AU2002322035A1 (en)	2002-12-16	Peptide deformylase inhibitors